David Paolella

I built a $100MM + clinical nutrition company (Cambrooke Therapeutics) and sold it to Ajinomoto in 2017. I acquired the assets of Milx Tech from the inventors when their startup failed and now looking to recap the business.

I trained as an architect but have been bumbling through tech startups since 1997. I've raised over $10MM in venture capital and built Cambrooke to serve clinical nutrition patients in more than 20 countries—culminating in a successful exit in 2017, where I remain a board member at Ajinomoto Cambrooke. I also serve on the board of Tandem Biotherapeutics and advise startups in digital health, medical devices, and clinical nutrition. I've had my fair share of misadventures licensing university tech and navigating regulatory mazes in over a dozen countries. I self-funded assets acquisition to build Milx Technologies. Now, I'm inviting a select group of investors to join our journey as we roll out Milx Technologies to a global audience.

introducing Milx—the newest form of milk since the invention of cheese! Our breakthrough process removes 85% of the water from fluid milk and packages it aseptically, so refrigeration is optional. When reconstituted, Milx delivers all the fresh milk taste and texture you love, with unmatched versatility. Milx is set to transform the global dairy supply chain—from the farm to the coffee shop—lowering carbon footprints while boosting nutrition and profits. Join us in revolutionizing dairy for a smarter, more sustainable future.